Theorem Clinical Research

Global News

Teva announces results of strategic review of core specialty therapeutic areas

Wednesday, October 8, 2014 01:49 PM

Teva Pharmaceutical Industries has identified 14 pipeline projects for discontinuation or divestment as part of its strategic review of core therapeutic areas for the company. These projects amount to more than $150 million in R&D costs in 2015 and in excess of $200 million for each of 2016 and 2017.

More... »


Merck Serono to collaborate with Institute of Cancer Research, Wellcome Trust

Wednesday, October 8, 2014 01:42 PM

Merck Serono, the Germany-based biopharmaceutical division of Merck; the London-based Institute of Cancer Research (ICR); and the Wellcome Trust, a U.K. charitable foundation, have announced a co-development and license agreement building on two independent research programs at both the ICR and Merck Serono to identify inhibitors of tankyrase, an enzyme of the poly (ADP-ribose) polymerase family.

More... »


Survey: CROs exchange regulated clinical trial docs via outdated methods

Wednesday, October 8, 2014 01:38 PM

The vast majority of CROs surveyed lag behind sponsors in how they exchange trial master file (TMF) documents, according to a Veeva Systems survey, Veeva 2014 Paperless TMF Survey: The State of CRO TMFs.

More... »

Epirus, Livzon Mabpharm collaborate in China

Wednesday, October 8, 2014 12:00 PM

Epirus Biopharmaceuticals, a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, has signed a royalty-bearing, multi-product collaboration agreement with Livzon Mabpharm, a Chinese biotechnology company focused on the development, manufacture and sale of antibody-based drugs.

More... »

Tenax Therapeutics halts phase IIb trial

Tuesday, October 7, 2014 01:00 PM

Tenax Therapeutics, formerly named Oxygen Biotherapeutics, a Morrisville, N.C.-based specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, has announced that the company, with unanimous approval from the board of directors, has elected to stop the current phase IIb trial for its Oxycyte drug candidate and consider strategic alternatives for the program moving forward. The company will review the data generated on the patients enrolled in the trial to date.

More... »

Optos, NHS, academia collaborate on early detection device

Tuesday, October 7, 2014 11:30 AM

Optos, a U.K. medical retinal imaging company, has announced a $16 million collaboration with scientists and clinicians from NHS Greater Glasgow and Clyde, and the Universities of Kent and Strathclyde, for the development of a new imaging technology that could allow earlier detection of sight threatening eye disease. 

More... »

PPD acquires X-Chem

Tuesday, October 7, 2014 10:30 AM

Pharmaceutical Product Development (PPD), a Wilmington, N.C.-based CRO, has exercised its option to acquire the remaining minority ownership interest of X-Chem. X-Chem, a biotechnology company based in Waltham, Mass., will continue to operate as a biotechnology company with its entire existing staff, including its management team led by CEO and founder Richard W. Wagner, Ph.D., along with executive management team members Diala Ezzeddine, Ph.D., chief business officer; Matthew Clark, Ph.D., sr. vice president of research; and Lee Babiss as chairman of the board.

More... »

HUYA Bioscience International, Tianjin Institute of Pharmaceutical Research partner

Tuesday, October 7, 2014 09:30 AM

HUYA Bioscience International, an accelerator of the global development of China’s pharmaceutical innovations, has announced a joint venture with Tianjin Institute of Pharmaceutical Research (TIPR) to develop medical technologies and therapies, originating in both China and the western world, for global markets.

More... »

Report: 310M diabetics with smart devices in 2018

Tuesday, October 7, 2014 09:00 AM

For the diabetes app industry, the addressable market will be 310 million diabetics with smart devices in 2018, according to the Diabetes App Market Report 2014, released by ReportsnReports.com.

More... »

Actavis to acquire Durata Therapeutics

Monday, October 6, 2014 04:00 PM

Actavis, a global specialty pharmaceutical company based in Dublin, Ireland, and Durata Therapeutics, an innovative pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses, headquartered in Chicago, Ill., have entered into a definitive merger agreement.

More... »

`
CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

October 27

NIH’s I-Corps boot camp aims to transform researchers into better businesspeople before they launch products

Covance, Frenova form partnership to share patient databases, find effective treatments for renal disease

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs